Ketamine Metabolites-waiting in the Wings as Therapeutic Candidate forDepression?

Ketamine and its metabolite (2R,6R)-hydroxynorketamine show rapid antidepressant effects in models of major depressive disorder. The review discusses how these compounds work differently from traditional antidepressants, potentially offering faster relief for treatment-resistant depression. The FDA-approved nasal spray Spravato (esketamine) is highlighted as a clinical application. The text suggests that understanding the mechanisms of these compounds could lead to better treatments for major depressive disorder.

Study at a glance

Abstract

Keywords: Ketamine, depression, antidepressant, 2R6R-hydroxynorketamine, major depressive disorder, Spravato